Although nonalcoholic fatty liver disease is the most prevalent liver disease worldwide, there is a paucity of good-quality data on its natural history and most studies to date have reported on retrospective data. Robust data are required to inform regulatory end points, trial design and models of care.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MicroRNA regulation of AMPK in nonalcoholic fatty liver disease
Experimental & Molecular Medicine Open Access 01 September 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
EASL, EASD & EASO. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-021-00523-4 (2021).
Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559–1569 (2021).
Bruden, D. J. T. et al. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. Hepatology 66, 37–45 (2017).
Rasmussen, D. N. et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J. Hepatol. 75, 1017–1025 (2021).
Ioannou, G. N., Green, P., Kerr, K. F. & Berry, K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J. Hepatol. 71, 523–533 (2019).
Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749–1761 (2014).
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J. Hepatol. 75, 659–689 (2021).
Majumdar, A., Campos, S., Gurusamy, K., Pinzani, M. & Tsochatzis, E. A. Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study. Hepatology 71, 627–642 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.A.T. serves on advisory boards for Engitix, Intercept, Gilead, NovoNordisk, Orphalan and Pfizer, and has received speaker fees from Intercept, Gilead, Oprhalan.
Rights and permissions
About this article
Cite this article
Tsochatzis, E.A. Natural history of NAFLD: knowns and unknowns. Nat Rev Gastroenterol Hepatol 19, 151–152 (2022). https://doi.org/10.1038/s41575-021-00565-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-021-00565-8
This article is cited by
-
Effects of Interventions for Improving Awareness and Knowledge of Nonalcoholic Fatty Liver Disease Among Chinese Young Adults for Prevention of Liver Cancer—A Randomized Controlled Trial
Journal of Cancer Education (2024)
-
MicroRNA regulation of AMPK in nonalcoholic fatty liver disease
Experimental & Molecular Medicine (2023)